*Disseminated on Behalf of Oncolytics Biotech Inc. Please see disclosures below. |
| This Company Is Making a Splash in Oncology... |
| | | | | Folks, In the fight against cancer, the immune system should be humanity's greatest ally. But cancer has learned to hide...
Tumors develop sophisticated methods to evade detection, essentially becoming invisible to the body's defenses. This immune evasion explains why even the most promising checkpoint inhibitors work in as few as 12.5% of patients. The immune system simply cannot target what it cannot see.
Oncolytics Biotech Inc. (ONCY) has developed pelareorep, a first-in-class oncolytic treatment designed to unmask cancer cells and turn the immune system back into the powerful weapon it was meant to be. | | | The Science Behind the Approach
Pelareorep is not a traditional drug. It is a nonpathogenic virus that can be delivered intravenously and works by selectively infecting cancer cells while leaving healthy tissue untouched. Once inside tumor cells, pelareorep triggers a cascade of immune responses that essentially sounds an alarm throughout the body.
What makes pelareorep unique is its ability to introduce double-stranded RNA directly into cancer cells. This acts as a powerful immune stimulant, causing the tumor to reveal itself to the immune system.
Key mechanisms of pelareorep include:
- Selective replication only within tumor cells, resulting in strong tolerability
- Enhanced T-cell infiltration and activation at tumor sites
- Remodeling of the tumor microenvironment to enable immune cell access
- Systemic activity that can reach both primary tumors and metastatic sites
Because pelareorep replicates exclusively in cancer cells, patients generally tolerate it well—a critical advantage for a therapy designed to work alongside other treatments.
A Combination Therapy Powerhouse
While pelareorep has demonstrated single-agent activity, its real potential may lie in combination with existing cancer treatments. The virus can work synergistically with a broad range of therapies to enhance their effectiveness.
Pelareorep has shown compatibility with:
✔️ Chemotherapy regimens ✔️ Immune checkpoint inhibitors (ICIs) ✔️ CAR T-cell therapy ✔️ Proteasome inhibitors ✔️ Bispecific antibodies ✔️ CDK4/6 and PARP inhibitors
This flexibility positions pelareorep as a potential addition to multiple treatment protocols across different cancer types. | | | Targeting High-Need Cancer Indications
Oncolytics has focused pelareorep development on cancers where current treatments fall short:
Metastatic Breast Cancer
HR+/HER2- breast cancer accounts for approximately 70% of all breast cancer cases. Despite initial responses to endocrine-blocking therapies, these tumors eventually develop resistance, with recurrence affecting roughly 50% of patients. Patients with advanced disease face a 5-year survival rate of only 28%.
The company's BRACELET-1 clinical trial is evaluating pelareorep in combination with chemotherapy and checkpoint inhibitors for patients with HR+/HER2- metastatic breast cancer.
Pancreatic Cancer
Pancreatic cancer remains the fourth leading cause of cancer-related death in the United States, with fewer than 10% of patients surviving beyond five years. These tumors are poorly immunogenic and show little response to existing immunotherapies.
Updated clinical data from pelareorep studies showed a 62% objective response rate—more than double historical control trial averages. The GOBLET trial continues to evaluate pelareorep in combination with atezolizumab for advanced pancreatic cancer.
Additional Indications Under Investigation
Ongoing studies are exploring pelareorep across multiple cancer types:
- Metastatic colorectal cancer
- Unresectable anal cancer
- Triple-negative breast cancer
- Multiple myeloma
- Various other GI malignancies
Regulatory Progress and Validation
The FDA has granted pelareorep Fast Track designation for two indications:
1. Metastatic breast cancer 2. Advanced/metastatic pancreatic ductal adenocarcinoma
These designations are designed to expedite the development and review of drugs intended to treat serious conditions where there is an unmet medical need. | | | Why This Approach Matters
The challenge with cancer immunotherapy has always been that tumors find ways to hide from the immune system. Checkpoint inhibitors were supposed to solve this problem, but response rates remain disappointingly low for many patients.
Pelareorep addresses this problem by unmasking cancer cells systemically...
Given the validity of the mechanism of action and the efficacy observed in clinical studies thus far, Oncolytics anticipates potential benefits extending across breast, gastrointestinal, and hematologic malignancies. |  | Worth Monitoring?
Oncolytics Biotech represents an intriguing approach to one of oncology's most persistent challenges. The company's oncolytic virus platform offers a differentiated mechanism that could complement the existing cancer treatment arsenal.
With Fast Track designations in hand and strong clinical data emerging from pancreatic cancer studies, ONCY may warrant attention from those following developments in cancer immunotherapy.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Oncolytics Biotech Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to stevenmagallanes520.nims@blogger.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via email and SMS on behalf of Oncolytics Biotech Inc. (ONCY) from February 3, 2026 to February 4, 2026. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Oncolytics Biotech Inc. (ONCY). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Oncolytics Biotech Inc. (ONCY). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Oncolytics Biotech Inc. (ONCY), increased trading volume, and possibly an increased share price of Oncolytics Biotech Inc. (ONCY), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
No comments:
Post a Comment